Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2016-02-16

Original market date: See footnote 1

2011-04-01

Product name:

REVOLADE

Description:

FILM-COATED

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section .

DIN:

02361833

Product Monograph/Veterinary Labelling:

Date: 2019-05-15 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company: 

NOVARTIS PHARMACEUTICALS CANADA INC
385 Bouchard Blvd
Dorval
Quebec
Canada  H9S 1A9

Class: 

Human

Dosage form(s):

Tablet

Route(s) of administration:

Oral

Number of active ingredient(s):

1

Schedule(s):

Prescription  

Biosimilar Biologic Drug:

No

American Hospital Formulary Service (AHFS): See footnote 3

20:16.00   HEMATOPOIETIC AGENTS

Anatomical Therapeutic Chemical (ATC): See footnote 4

B02BX05  ELTROMBOPAG

Active ingredient group (AIG) number:See footnote 5

0152873002

List of active ingredient(s)
Active ingredient(s) Strength
ELTROMBOPAG (ELTROMBOPAG OLAMINE) 50 MG

Risk Management Plans See footnote 7

A Risk Management Plan (RMP) for this product was submitted.

Application information

Related information

Contact us

Version 3.8.0
Date modified: